Dr. Monty Pal discusses the growing importance of quality of life and long-term tolerability when selecting subsequent ...

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 in favor of the IGNYTE study (NCT03767348) supporting the potential accelerated approval of vusolimogene oderparepvec (RP1; ...

Dr. Monty Pal discusses how patient- and disease-specific characteristics influence treatment sequencing decisions for advanced renal cell carcinoma (RCC) beyond the first-line setting.

The single-arm trial met its primary end point of complete response (CR) at any time, exceeding historic and contemporary ...

Chromosome 13q linkage promotes RB1 hemizygosity during BRCA2 LOH, lowering the ‘two-hit’ barrier and predisposing to ...

New KRAS-targeting drug for metastatic pancreatic cancer nearly doubles second-line survival; expert explains impact, side effects, next trials.

Betts, MD, discusses how PTCy and tacrolimus protocols, as well as using younger donors, contributes to higher survival rates ...

MCED screening and broader genetic testing push community oncology toward prevention—learn how practices adapt workflows, ...

Objective response rate was 35% (3 CR, 3 PR), with most patients demonstrating primary progression despite meeting ...

Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks ...

Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...